quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:01:15·65d
SECFiling
Outlook Therapeutics Inc. logo

SEC Form 10-Q filed by Outlook Therapeutics Inc.

OTLK· Outlook Therapeutics Inc.
Health Care
Original source

Companies

  • OTLK
    Outlook Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 29UpdateH.C. Wainwright-
  • Aug 28UpdateGuggenheim-
  • Dec 2UpdateChardan Capital Markets-
  • Mar 27UpdateBTIG Research$50.00
  • Feb 15UpdateChardan Capital Markets$3.00
  • Jan 25UpdateGuggenheim-

Related

  • SEC17h
    Outlook Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
  • PR17h
    Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
  • SEC1d
    SEC Form 424B5 filed by Outlook Therapeutics Inc.
  • PR2d
    Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
  • SEC2d
    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events
  • PR3d
    Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
  • SEC16d
    Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events
  • PR17d
    Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022